Benzinga · Oct 5, 2026
HC Wainwright & Co. Reiterates Sell on Sarepta Therapeutics, Maintains $5 Price Target
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Sarepta Therapeutics (NASDAQ:SRPT) with a Sell and maintains $5 price target.
SR
NASDAQ · SRPT
Sarepta Therapeutics, Inc.
Healthcare · Biotechnology
$17.49
Down-$0.18 (-1.03%)
Updated Oct 6, 2026, 10:38 PM
SID Score
4.3/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 2.13B
- P/E ratio
- -7.89
- Dividend yield
- 0.00%
- 52-week range
- $14.68 – $23.85
- Volume
- 2.2M
- Avg. volume
- 5.43M
Price performance · SRPT
SRPT price history
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 5, 2026
SRPT closed at $17.49 after 20 trading sessions, down 16.48% for the selected period.
- Last close
- $17.49
- Period change
- -16.48%
- Period low
- $17.49
- Period high
- $22.02
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 5, 2026 | $17.385 | $17.55 | $17.10 | $17.49 | 2.2M |
| Oct 2, 2026 | $17.75 | $17.76 | $17.21 | $17.50 | 2.55M |
| Oct 1, 2026 | $18.14 | $18.25 | $17.52 | $17.57 | 2.89M |
| Sep 30, 2026 | $18.64 | $18.69 | $18.06 | $18.22 | 2M |
| Sep 29, 2026 | $18.675 | $18.74 | $18.38 | $18.64 | 1.37M |
| Sep 28, 2026 | $18.43 | $18.855 | $17.64 | $18.80 | 2.27M |
| Sep 25, 2026 | $18.49 | $18.77 | $18.015 | $18.67 | 2.22M |
| Sep 24, 2026 | $18.845 | $19.14 | $18.05 | $18.39 | 2.56M |
| Sep 23, 2026 | $20.72 | $20.7572 | $18.735 | $18.95 | 3.76M |
| Sep 22, 2026 | $20.46 | $21.185 | $20.19 | $20.81 | 2.19M |
| Sep 21, 2026 | $20.29 | $20.50 | $19.965 | $20.14 | 1.76M |
| Sep 18, 2026 | $20.63 | $20.74 | $19.62 | $20.11 | 6.29M |
| Sep 17, 2026 | $20.23 | $21.75 | $19.97 | $20.67 | 2.59M |
| Sep 16, 2026 | $20.68 | $20.89 | $19.72 | $19.76 | 2.51M |
| Sep 15, 2026 | $20.81 | $21.06 | $20.29 | $20.72 | 2.53M |
| Sep 14, 2026 | $20.55 | $21.40 | $20.38 | $20.92 | 2.19M |
| Sep 11, 2026 | $20.76 | $21.10 | $20.29 | $20.45 | 1.81M |
| Sep 10, 2026 | $22.02 | $22.02 | $20.28 | $20.52 | 2.2M |
| Sep 9, 2026 | $20.805 | $23.22 | $20.63 | $22.02 | 4.17M |
| Sep 8, 2026 | $19.86 | $21.32 | $19.51 | $20.94 | 6.24M |
Latest SRPT news
The latest Smart Investors Daily articles mentioning SRPT.
Stock researchCompany · Overview
Company
Market Activity
Research & News
SRPT research
Overview
Company profile and research snapshot.
Company profile
Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Majority of company's product candidates are at an early stage of development.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $25.92
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 5, 2026 | HC Wainwright & Co. | Sell | — |
| Sep 30, 2026 | JP Morgan | Neutral | — |
| Sep 28, 2026 | Needham | Underperform | — |
| Jul 9, 2026 | Piper Sandler | Neutral | — |
| Jul 9, 2026 | Wolfe Research | Outperform | — |
News briefing
No generated briefing is available yet.
Yahoo · Sep 30, 2026
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., September 30, 2026--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on Sept. 30, 2026 that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2024 Employment Commencement Incentive Plan, as a material inducement to employment to 37 individuals hired by Sarepta in the third quarter of 2026. The equity awards were approved in accordance with Nasdaq Listing Rul
Benzinga · Sep 30, 2026
JP Morgan Maintains Neutral on Sarepta Therapeutics, Lowers Price Target to $20
JP Morgan analyst Anupam Rama maintains Sarepta Therapeutics (NASDAQ:SRPT) with a Neutral and lowers the price target from $23 to $20.
SeekingAlpha · Sep 30, 2026
Dyne: Recent Price Drop On Rival's DM1 Data Creates (Risky) 'Buy The Dip' Scenario
Dyne Therapeutics is reiterated as a "risky Buy" following a >30% stock decline, presenting a contrarian opportunity. Click for this DYN stock update.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
